1. |
Kaier K. Economic implications of the dynamic relationship between antibiotic use and hospital-acquired infections. Value Health, 2012, 15(1): 87-93.
|
2. |
O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance, 2016: 1-16.
|
3. |
刘越男, 张艳晶, 呼明明, 等. 浅谈国外抗生素管理策略. 中国新药杂志, 2014, 23(15): 1836-1842.
|
4. |
Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ, 1996, 5(3): 217-226.
|
5. |
Coast J, Smith R, Karcher AM, et al. Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? Health Econ, 2002, 11(7): 637-647.
|
6. |
Smith RD, Yago M, Millar M, et al. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy, 2006, 5(1): 55-65.
|
7. |
Morton A, Colson A, Leporowski A, et al. How should the value attributes of novel antibiotics be considered in reimbursement decision making? MDM Policy Pract, 2019, 4(2): 2381468319892237.
|
8. |
Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care, Spring 2005, 21(2): 240-245.
|
9. |
王莉, 胡善联, 孙鑫, 等. 卫生经济学分析的系统评价方法与挑战. 中国循证医学杂志, 2008, 8(11): 1007-1011.
|
10. |
Goh KL, Cutler A, Chua AB, et al. Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients. J Gastroenterol Hepatol, 1999, 14(1): 32-38.
|
11. |
Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health, 2009, 12(2): 234-244.
|
12. |
Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics, 2009, 27(12): 1045-1056.
|
13. |
Kongnakorn T, Eckmann C, Bassetti M, et al. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrob Resist Infect Control, 2019, 8: 204.
|
14. |
Kongnakorn T, Wagenlehner F, Falcone M, et al. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. Int J Antimicrob Agents, 2019, 54(5): 633-641.
|
15. |
Lee K, Drekonja DM, Enns EA. Cost-effectiveness of antibiotic prophylaxis strategies for transrectal prostate biopsy in an era of increasing antimicrobial resistance. Value Health, 2018, 21(3): 310-317.
|
16. |
Lin YJ, Lin HC, Yang YF, et al. Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan. Int J Infect Dis, 2020, 97: 135-142.
|
17. |
Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother, 2007, 59(5): 977-989.
|
18. |
O'Neill C, Gibson PG, Heaney LG, et al. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Eur Respir J, 2021, 57(2): 2002436.
|
19. |
Oppong R, Smith RD, Little P, et al. Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. Br J Gen Pract, 2016, 66(650): e633-639.
|
20. |
Sabes-Figuera R, Segú JL, Puig-Junoy J, et al. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ, 2008, 9(1): 23-32.
|
21. |
Sadler S, Holmes M, Ren S, et al. Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics. BJGP Open, 2017, 1(3): bjgpopen17X101097.
|
22. |
Wang R, Hacker MR, Lefevre R. Cost-effectiveness of prophylactic antibiotic use to prevent catheter-associated urinary tract infections. Int Urogynecol J, 2020, 31(2): 285-289.
|
23. |
张璐莹. 厄他培南对比哌拉西林/他唑巴坦治疗复杂性腹腔感染的成本效果-分析. 中国药物评价, 2017, 34(5): 386-389.
|
24. |
Sharma A. Antimicrobial resistance: no action today, no cure tomorrow. Indian J Med Microbiol, 2011, 29(2): 91-92.
|
25. |
Hicks LA, Taylor TH, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med, 2013, 368(15): 1461-1462.
|
26. |
European Centre for Disease Prevention and Control EMA. The bacterial challenge: time to react. Joint technical report. Stockholm: ECDPC, 2009.
|
27. |
European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union. Stockholm: ECDPC, 2014.
|
28. |
Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis, 2014, 14(8): 742-750.
|
29. |
Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control, 2018, 7: 98.
|
30. |
MacAdam H, Zaoutis TE, Gasink LB, et al. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents, 2006, 28(4): 325-332.
|
31. |
Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis, 2009, 22(4): 352-358.
|
32. |
Holmes EAF, Hughes DA. Challenges for economic evaluation of health care strategies to contain antimicrobial resistance. Antibiotics (Basel), 2019, 8(4): 166.
|
33. |
Franklin M, Thorn J. Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future. BMC Med Res Methodol, 2019, 19(1): 8.
|
34. |
Wisløff T, Hagen G, Hamidi V, et al. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics, 2014, 32(4): 367-375.
|
35. |
Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis, 2019, 19(1): 56-66.
|